Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Detection of overall and index prostate cancer is comparable in three Tesla multiparametric magnetic resonance imaging (MRI) with and without an endorectal coil, a study has found. However, the endorectal coil subcohort has markedly higher detection of posterior and peripheral prostate cancer, as well as detection of anterior and transition zone prostate cancer.
Radical prostatectomy can provide long-term survival benefits and reduce the risk of distant metastasis in otherwise healthy men with clinically detected, localized prostate cancer, according to findings from 23 years of follow-up of the SPCG-4 study (Scandinavian Prostate Cancer Group Study Number 4).
Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.
External beam radiation therapy is a standard option for the initial management of men with localized prostate cancer, and a new guideline states that hypofractionation of radiation treatment confers benefits for cost and convenience.
There is only a slight improvement in prostate cancer detection rate and Gleason grading as a result of obtaining more than one biopsy core per magnetic resonance imaging (MRI) lesion, a study has shown.
Use of multiparametric magnetic resonance imaging (MRI) significantly lowers the number of unnecessary repeat prostate biopsies in about 50 percent of cases in which a Prostate Imaging Reporting and Data System (PI-RADS) score of ≥3 is used, a recent study has shown.
The increased risk of prostate cancer, particularly early-onset prostate cancer, among subfertile men who undergo intracytoplasmic sperm injection (ICSI) does not appear to be due to the procedure, according to a nationwide, registry-based study from Sweden.
Treatment with abiraterone acetate plus prednisone results in a significant ≥50-percent prostate-specific antigen reduction in patients with high-risk, nonmetastatic, castration-resistant prostate cancer, a study has shown.
Bilateral nerve sparing (BNS) is better than unilateral (UNS) and non-nerve sparing (NNS) in terms of sexual and urinary function outcomes in men diagnosed with localized prostate cancer who underwent radical prostatectomy, according to the CEASAR* study. However, the difference is not significant in men with low baseline sexual function.